Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Development ; 144(14): 2629-2639, 2017 07 15.
Article in English | MEDLINE | ID: mdl-28619820

ABSTRACT

Arterial specification and differentiation are influenced by a number of regulatory pathways. While it is known that the Vegfa-Notch cascade plays a central role, the transcriptional hierarchy controlling arterial specification has not been fully delineated. To elucidate the direct transcriptional regulators of Notch receptor expression in arterial endothelial cells, we used histone signatures, DNaseI hypersensitivity and ChIP-seq data to identify enhancers for the human NOTCH1 and zebrafish notch1b genes. These enhancers were able to direct arterial endothelial cell-restricted expression in transgenic models. Genetic disruption of SoxF binding sites established a clear requirement for members of this group of transcription factors (SOX7, SOX17 and SOX18) to drive the activity of these enhancers in vivo Endogenous deletion of the notch1b enhancer led to a significant loss of arterial connections to the dorsal aorta in Notch pathway-deficient zebrafish. Loss of SoxF function revealed that these factors are necessary for NOTCH1 and notch1b enhancer activity and for correct endogenous transcription of these genes. These findings position SoxF transcription factors directly upstream of Notch receptor expression during the acquisition of arterial identity in vertebrates.


Subject(s)
Arteries/embryology , Arteries/metabolism , Receptor, Notch1/genetics , Receptor, Notch1/metabolism , SOXF Transcription Factors/genetics , SOXF Transcription Factors/metabolism , Amino Acid Sequence , Animals , Animals, Genetically Modified , Arteriovenous Malformations/embryology , Arteriovenous Malformations/genetics , Arteriovenous Malformations/metabolism , Enhancer Elements, Genetic , Female , Gene Expression Regulation, Developmental , Human Umbilical Vein Endothelial Cells , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Pregnancy , Receptor, Notch1/deficiency , SOXF Transcription Factors/deficiency , Sequence Homology, Amino Acid , Signal Transduction , Zebrafish , Zebrafish Proteins/deficiency , Zebrafish Proteins/genetics , Zebrafish Proteins/metabolism
3.
Oncotarget ; 7(19): 27802-18, 2016 May 10.
Article in English | MEDLINE | ID: mdl-27050151

ABSTRACT

Emerging biological and translational insights from large sequencing efforts underscore the need for genetically-relevant cell lines to study the relationships between genomic alterations of tumors, and therapeutic dependencies. Here, we report a detailed characterization of a novel panel of clinically annotated oral squamous cell carcinoma (OSCC) cell lines, derived from patients with diverse ethnicity and risk habits. Molecular analysis by RNAseq and copy number alterations (CNA) identified that the cell lines harbour CNA that have been previously reported in OSCC, for example focal amplications in 3q, 7p, 8q, 11q, 20q and deletions in 3p, 5q, 8p, 18q. Similarly, our analysis identified the same cohort of frequently mutated genes previously reported in OSCC including TP53, CDKN2A, EPHA2, FAT1, NOTCH1, CASP8 and PIK3CA. Notably, we identified mutations (MLL4, USP9X, ARID2) in cell lines derived from betel quid users that may be associated with this specific risk factor. Gene expression profiles of the ORL lines also aligned with those reported for OSCC. By focusing on those gene expression signatures that are predictive of chemotherapeutic response, we observed that the ORL lines broadly clustered into three groups (cell cycle, xenobiotic metabolism, others). The ORL lines noted to be enriched in cell cycle genes responded preferentially to the CDK1 inhibitor RO3306, by MTT cell viability assay. Overall, our in-depth characterization of clinically annotated ORL lines provides new insight into the molecular alterations synonymous with OSCC, which can facilitate in the identification of biomarkers that can be used to guide diagnosis, prognosis, and treatment of OSCC.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/genetics , Molecular Targeted Therapy , Mouth Neoplasms/drug therapy , Mouth Neoplasms/genetics , Animals , Antineoplastic Agents/pharmacology , Areca/adverse effects , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , DNA Copy Number Variations , Female , Gene Amplification , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Genes, Neoplasm/genetics , Humans , Mice , Mice, Inbred NOD , Mice, SCID , Mouth Neoplasms/pathology , Mutation , Sequence Analysis, RNA , Sequence Deletion , Transcriptome , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL